| Ytd | -19.31% | |
| 1y | -34.80% |
| Open | 1.57 | Prev Close | 1.57 | Low | 1.56 | High | 1.63 | Mkt Cap | 230.02M |
| Vol | 676.09K | Avg Vol | 796.42K | EPS | -0.45 | P/E | N/A | Forward P/E | -5.68 |
| Beta | 0.25 | Short Ratio | 0.31 | Inst. Own | 24.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 1.92 | 200-d Avg | 1.74 | 1yr Est | 8.00 |
PRQR News
HC Wainwright & Co. analyst Ananda Ghosh maintains ProQR Therapeutics (NASDAQ:PRQR) with a Bu
U.S. stock futures mixed, Nasdaq 100 up 0.1%. Coty Inc (COTY) shares down 7.7% after reporting losse
B of A Securities analyst Alec Stranahan initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) w
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which beat the analy
Evercore ISI Group analyst Gavin Clark-Gartner maintains ProQR Therapeutics (NASDAQ:PRQR) with a
Top analysts change outlook on top names: BMO, Chardan, Rosenblatt, Susquehanna, Evercore, Deutsche
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowe
ProQR reported positive AX-0810 Phase 1 data and raised $50 million, with Eli Lilly joining a concur
ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a clinical-stage biotechnology company dedi
Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.15) per share which met the analys
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transf
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which missed the ana
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.10) per share which met the analys
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and main
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transf
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and main
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the ana
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the ana
Cantor Fitzgerald analyst Timur Ivannikov reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Over
JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Marke
Oppenheimer analyst Andreas Argyrides maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperfor
Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on ProQR Therapeutics (NASDAQ:P
Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourt
Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is estimated to report quarterly ear
On Wednesday, 807 companies reached new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
On Friday, 213 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week
On Wednesday, 160 companies hit new 52-week lows.
On Monday, 466 companies hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.
On Friday, 368 stocks hit new 52-week lows.
On Wednesday, 115 companies reached new 52-week lows.
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insid
On Friday, 106 companies reached new 52-week lows.
Thursday morning saw 23 companies set new 52-week highs.
During Wednesday's morning trading, 129 companies set new 52-week lows. Areas of Interest: T
Gainers Aimmune Therapeutics, Inc (NASDAQ: AIMT) shares jumped 171.6% to close at $34.22 on Monda
Stocks That Hit 52-Week Lows On Monday
108 Biggest Movers From Yesterday
26 Stocks Moving in Wednesday's Pre-Market Session
Stocks That Hit 52-Week Lows On Wednesday
76 Biggest Movers From Yesterday
Stocks Which Set New 52-Week High Yesterday, September 11th